question · intermediate · partly written
Can a gene delivered by AAV be turned down or off after dosing in people?
Regulated expression is well described as a design goal, but no opened source shows a clinical AAV product with a working off-switch.
The question in brief
A promoter sets how strongly a delivered gene is read; how long it lasts comes from the form of the vector DNA. 12
Reported, not yet replicated
Observation
Hypotheses
Promoter-based control
A tissue-specific or inducible promoter sets how strongly the gene is read. 1
Predicts. Expression follows the signal.
Would falsify. No change with the signal in humans.
Our inference
What is missing
Clinical evidence
A clinical AAV product with a drug-controlled expression switch and published human data. 1
Our inference
What is known
What is not
What would settle it
Still open here
- Is there a clinical regulated AAV product?
Not yet written: Who works on it.
Sources
- Butterfield et al.. Gene regulation technologies for gene and cell therapy (Mol Ther 2025, 33(5); title taken from the file name of the hosted PDF). Molecular Therapy (2025). review; opened 2026-11-17 all records citing this
- US Food and Drug Administration. ZOLGENSMA (onasemnogene abeparvovec-xioi) prescribing information, revision 6/2026. FDA (2026). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
History of this record (1)
This record has been changed 1 time, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.
- Kind
- big-open
- Register
- open-question
- Triage
- needs-research
- Status
- partly written
- Last updated
- 2026-11-17
- Record
- content/questions/can-aav-gene-expression-be-switched-off-after-dosing.json